Overestimated risk of second primary malignancies in ovarian cancer patients

534 Background: Survival of cancer patients is increasing. Therefore, there is a need to evaluate long term complications in cancer survivors. There is no data on second primary malignancies in anal cancer. This study was conducted to evaluate second primary malignancies in patients with anal carcinoma. Methods: We selected adult patients diagnosed with anal cancer from National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) 13 database We calculated the risk of second primary malignancies in the anal cancer patients using multiple primary standardized incidence ratio (MP-SIR) session of SEER*stat software. Results: Among 7,661 patients with anal carcinoma, 3,196 were men and 4,465 were women. Median follow up duration was 87 months (range: 7-239 months). Median age at the time of diagnosis of SPM was 69.33 yrs (range: 34-103 yrs). Median latency for SPM was 52 months (range: 6-219 months). A total of 675 patients (9.07%) developed 747 second primary malignancies, with an observed/expected (O/E) ratio of 1.41 (95% confidence interval =1.32-1.52, p<0.001), and an absolute excess risk of 55.36 per 10,000 populations. Significant excess risks were observed for oral cavity and pharyngeal tumor, rectal and anal canal tumor, laryngeal tumor, lung and bronchial cancer, Kaposi sarcoma, hematologic malignancies, ovarian, vaginal, and vulval tumors. Conclusions: The risk of second primary malignancies in adult patients with anal cancer is significantly increased compared to general population.

Download Full-text

SECOND PRIMARY MALIGNANCIES IN T1-3N0 PROSTATE CANCER PATIENTS TREATED WITH RADIATION THERAPY WITH 10-YEAR FOLLOWUP

The Journal of Urology ◽

10.1097/00005392-199803000-00089 ◽

1998 ◽

pp. 946-949 ◽

Cited By ~ 1

Author(s):

PETER A. S. JOHNSTONE ◽

CURT R. POWELL ◽

ROBERT RIFFENBURGH ◽

DAVID C. ROHDE ◽

CHRISTOPHER J. KANE

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Cancer Patients ◽

Second Primary ◽

Second Primary Malignancies

Download Full-text

Treatment strategy for the head and neck cancer patients with synchronous second primary malignancies

Toukeibu Gan ◽

10.5981/jjhnc.34.14 ◽

2008 ◽

Vol 34 (1) ◽

pp. 14-18 ◽

Cited By ~ 2

Author(s):

Kiyoto Shiga ◽

Toshimitsu Kobayashi

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Treatment Strategy ◽

Second Primary ◽

Second Primary Malignancies

Download Full-text

PO-051 Familial risks and mortality in second primary cancers of ovarian cancer patients

10.1136/esmoopen-2018-eacr25.584 ◽

2018 ◽

Author(s):

G Zheng ◽

S Chattopadhyay ◽

A Kanerva ◽

A Försti ◽

K Sundquist ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Second Primary ◽

Second Primary Cancers

Download Full-text

Second primary cancer of the larynx in patients with lung cancer

The Journal of Laryngology & Otology ◽

10.1017/s0022215100158293 ◽

1998 ◽

Vol 112 (3) ◽

pp. 252-257 ◽

Cited By ~ 1

Author(s):

Yoav P. Talmi ◽

Lev Bedrin ◽

Alexander Waller ◽

Zeev Horowitz ◽

Yair Skurnik ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Laryngeal Cancer ◽

Second Primary ◽

Second Primary Cancer ◽

Lung Cancers ◽

Lung Cancer Patients ◽

Large Databases ◽

Second Primary Malignancies ◽

Cancer Of The Lung

AbstractSynchronous or metachronous second primary malignancies of the lung are sometimes encountered in patients with laryngeal cancer while the occurrence of a laryngeal second primary following cancer of the lung is rare.A two-armed study was conducted. A prospective arm in which the larynges of 56 terminal lung cancer patients were examined, and a retrospective arm incorporating both a chart study of 126 terminal head and neck cancer patients (HNCP) and a computerized search of all hospital records of patients with laryngeal and lung cancers. No laryngeal malignancy was found in the lung cancer patients' group and no antedating pulmonary malignancy was recorded in the terminal HNCP. The computerized search of 1778 lung cancer patients and 213 laryngeal cancer patients also failed to demonstrate cases where the former preceded the latter.In conclusion. No second primary of the larynx was found in lung cancer patients. These results compare with reports of large databases where cancer of the larynx was found in a negligible percentage of lung cancer survivors and theories explaining this are discussed.

Download Full-text

Second primary malignancies of cancer patients: treatment-related carcinogenesis

Advances in molecular oncology ◽

10.17650/2313-805x-2016-3-3-44-55 ◽

2016 ◽

Vol 3 (3) ◽

pp. 44-55 ◽

Cited By ~ 2

Author(s):

G. A. Belitskiy ◽

E. A. Lesovaya ◽

K. I. Kirsanov ◽

M. G. Yakubovskaya

Keyword(s):

Cancer Patients ◽

Second Primary ◽

Second Primary Malignancies

Download Full-text

The Aberrant Expression Levels of miR-423-5p and miR-664b-5p in Peripheral Blood of Patients With Familial and Sporadic Ovarian Carcinoma

10.21203/rs.3.rs-84141/v1 ◽

2020 ◽

Author(s):

BUSRA KURT ◽

Seref Bugra TUNCER ◽

Demet AKDENIZ ODEMIS ◽

Arash ADAMNEJAD GHAFOUR ◽

Mukaddes Avsar Sarali ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patient ◽

Cancer Patients ◽

Peripheral Blood ◽

Ovarian Cancer Patient ◽

Expression Level ◽

Control Group ◽

Second Primary ◽

Aberrant Expression ◽

Significant Difference

Abstract MicroRNAs (miRNAs), are endogenous noncoding single strand RNA molecules with approximate length of 22 nucleotides. Ovarian cancer is a heterogenous disease which includes different biologic behaviors in the clinical, and molecular level. miRNAs have roles in the early diagnosis, prognosis, and chemotherapy sensitivity for ovarian cancer, and in the regulation of reproduction by being expressed in the ovaries. The expression level of two miRNAs of miR-423-5p, and miR-664b-5p selected from the miRNAs which were detected to be important for the ovarian cancer etiology in our previous studies were investigated in the peripheral blood of familial and sporadic ovarian cancer patients, and in healthy individuals. The expression analyses were statistically evaluated with SPSS v21.0 program using the Quantitative Real-Time PCR technique. A statistically significant difference was detected for both miRNAs between the healthy controls and ovarian cancer patient groups (p:0.000). The miR-423-5p expression was detected to increase 2.35 fold, and miR-664b-5p was detected to increase 2.47 fold in ovarian cancer patients compared with the levels in the control group. miR-423-5p was reported to be overexpressed in various cancer types, and in different disease stages in previous study, and miR-423-5p was demonstrated to have increased in the lymphocytes in the peripheral circulation of ovarian cancer patients first in our literature. The miR-664b-5p expression level was detected in high levels in ovarian cancer patient group, however was detected to have decreased in 64% of ovarian cancer patients with BRCA mutation carrier. The expressions of both miRNA molecules were detected to have decreased in the ovarian cancer subgroups in patients with ovarian cancer with addition of a second primary cancer of endometrium cancer, however, were detected in the highest level in ovarian cancer patients in addition to another secondary cancer except breast and endometrium cancer. The results obtained from the study showed that the increased expression of both miRNA molecules were suggested to be associated with ovarian cancer, and decrease was suggested to be associated with endometrium cancer. In summary, the miRNA molecules in the present study might be the non-invasive biological indicator in ovarian cancer, and the demonstration of these molecules on the tumor tissue, and their change during treatment in future studies will be beneficial.

Download Full-text